Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab...

  • Main
  • 2016 / 2
  • Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab...

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Sattar, Naveed, Preiss, David, Robinson, Jennifer G, Djedjos, C Stephen, Elliott, Mary, Somaratne, Ransi, Wasserman, Scott M, Raal, Frederick J
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(16)00003-6
Date:
February, 2016
File:
PDF, 484 KB
english, 2016
Conversion to is in progress
Conversion to is failed